WCN26-6423 Pemigatinib-Associated Calciphylaxis versus Calcinosis Cutis in Metastatic Cholangiocarcinoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research investigates the metabolic impacts of SGLT2 inhibition on cholangiocarcinoma, particularly focusing on metabolic remodeling and energy metabolism shifts.
Conducted multivariate statistical analyses (PCA, PLS-DA, OPLS-DA) to identify altered metabolites.
Performed pathway enrichment and network analysis for metabolic rewiring exploration.
Utilized western blotting to validate pathway-specific metabolic changes.
SGLT2 inhibition led to biphasic metabolic remodeling with initial activation of fatty acid oxidation and urea cycle.
Early metabolic changes included elevated acetyl-CoA and ketone bodies, alongside AMPK and PGC-1 activation.
Later phases revealed sustained upregulation of TCA cycle intermediates and nucleotide biosynthesis, indicating improved mitochondrial function.

This analysis demonstrates metabolic changes in cholangiocarcinoma, suggesting potential targeted therapy approaches.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Singh et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share